BrainXell Therapeutics
PrivateLast Round
Grant
Mar 26, 2025
Total Funding Raised
$20.17M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
BrainXell Therapeutics is a biotechnology company that develops autologous, iPSC-derived cell therapies to treat neurodegenerative diseases such as Parkinson's disease and spinal cord injuries.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BrainXell Therapeutics Comparables
Compare BrainXell Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kenai Therapeutics | 88% | |
| Aspen Neuroscience | 87% | |
| iRegene Therapeutics | 80% |
BrainXell Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 26, 2025 | ||||
| Grant | May 1, 2023 | ||||
| Grant | Jan 26, 2023 | ||||
| Series B | Sep 13, 2021 | ||||
| Grant | Nov 1, 2016 |
BrainXell Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
| Discovery to Product | Grant |
| California Institute for Regenerative Medicine | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 16, 2026
Monthly visitors increased 85% MoM.
- Mar 26, 2025
$4M grant from California Institute for Regenerative Medicine
BrainXell Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about BrainXell Therapeutics's valuation, stock price, and market status.
Is BrainXell Therapeutics a public or private company?
BrainXell Therapeutics is a private company.
What is the current stock price of BrainXell Therapeutics?
BrainXell Therapeutics is a private company with no public stock price. Caplight tracks BrainXell Therapeutics's secondary market activity and provides MarketPrice™ estimates to Caplight users.
How much is BrainXell Therapeutics worth (valuation)?
Valuation information for BrainXell Therapeutics is not publicly available.
Can I buy BrainXell Therapeutics stock?
BrainXell Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was BrainXell Therapeutics's last funding round?
BrainXell Therapeutics's most recent funding round was Grant on March 26, 2025.
Who are the main investors in BrainXell Therapeutics?
Key investors in BrainXell Therapeutics include NIH RADx, Discovery to Product, California Institute for Regenerative Medicine.
Will BrainXell Therapeutics IPO soon?
No public IPO plans have been announced for BrainXell Therapeutics.
How can I track BrainXell Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor BrainXell Therapeutics's secondary market activity and sign up for updates.